Skip to content

Strategy of Transfusion in Trauma Patients - STATA Trial

Clinical Trial: Evaluation of 2 Different Protocols of Blood Derivates Transfusion in Acute Trauma Patients in a Brazilian Tertiary Hospital

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02416817
Acronym
STATA
Enrollment
156
Registered
2015-04-15
Start date
2014-07-31
Completion date
2016-07-31
Last updated
2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wounds and Injuries

Keywords

Thrombelastography, Massive Transfusion, Major Trauma, Blood products, Thromboelastometry

Brief summary

The purpose of this study is to compare two already validated methods for massive transfusion in trauma patients admitted to the emergency room of a large reference hospital.

Detailed description

In this randomized trial trauma patients in need of massive transfusion will be assigned to one of the following transfusion strategies: 1. \- Fresh Frozen Plasma, Platelets Concentrate and Packed red blood cells in 1:1:1 ratio. 2. \- These patients will receive Red blood cells based on Haemoglobin measurements and will receive either Beriplex® P/N (CSL Behring GmbH, Marburg, Germany) or Haemocomplettan® P (CSL Behring, Marburg, Germany), or Platelets based on thromboelastometry. To be included patients must meet the following inclusion criteria: 1. \- Trauma victims 2. \- Adults between 18 - 80 years old 3. \- Injury Severity Score (ISS) between 15 and 45 4. \- Assessment of Blood Consumption (ABC) Score ≥ 3 points 5. \- Shock Index ≥ 1,2 6. \- Acute hemorrhage of more than 50% estimated blood volume in 3 hours or more than 1,5 ml/kg/min of blood during 20 minutes. Exclusion Criteria: 1. \- Early cardiac arrest 2. \- Pregnancy 3. \- Injury Severity Score (ISS) \> 45 4. \- Patient transferred from another hospital 5. \- Drug abuse history 6. \- Known coagulation impairment 7. \- Known use of anticoagulants, or platelet antiaggregants. The group of health-care providers recruiting the patients based on eligibility criteria, is different than the group that evaluates the clinical outcomes of the included patients, in such a way that no researcher is tasked with post-randomisation care of the subjects. This is done to prevent observational bias. Two informed consent forms are signed for each patient. The first one is signed by an independent physician. Another consent form is signed by the patient's family or the own patient within 24 hours of hospital admission. The randomisation is performed by sealed envelopes assigned to the eligible patients anytime they reach the protocol criteria. The envelopes were created using a computer generated randomisation table specifically designed to this study. An interim analysis was performed in October 2015 and it showed that there was no increased mortality or morbidity within the intervention group.

Interventions

OTHERBlood Products only

Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.

OTHERPoint of Care guided

Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Trauma victims * Adults between 18 - 80 years old * Injury Severity Score (ISS) between 15 and 45 * Assessment of Blood Consumption (ABC) Score ≥ 3 points * Shock Index ≥ 1,2

Exclusion criteria

* Early cardiac arrest * Pregnancy * ISS \> 45 * Patient transferred from another hospital * Drug abuse history * Known coagulation impairment * Known use of anticoagulants, or platelet anti-aggregants. -

Design outcomes

Primary

MeasureTime frameDescription
SOFA Score - 5 days5 daysEvaluation of the SOFA score along the first 5 days after the patient admission.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026